In a 50-year-old man with a history of renal cell carcinoma status post left nephrectomy, hypertension treated with amlodipine (Norvasc), presenting with two weeks of severe generalized weakness, dizziness, abdominal distention, hyponatremia (serum sodium 125 mmol/L) and hyperkalemia (serum potassium 5.5 mmol/L), what is the appropriate diagnostic workup and immediate management?

Immediate Management: Adrenal Insufficiency Until Proven Otherwise

This patient requires immediate evaluation for adrenal insufficiency (AI) secondary to metastatic renal cell carcinoma, with urgent measurement of morning cortisol and ACTH, followed by empiric stress-dose hydrocortisone if AI is confirmed or highly suspected. The combination of severe weakness, dizziness, hyponatremia (125 mmol/L), hyperkalemia (5.5 mmol/L), and a 4 cm adrenal mass in a patient with prior RCC strongly suggests adrenal metastases causing primary adrenal insufficiency.

Diagnostic Workup Priority

First-Line Critical Tests (Obtain Immediately)

• Morning (8 AM) serum cortisol and ACTH - This is the single most important test. A morning cortisol <3 μg/dL confirms AI; 3-15 μg/dL requires ACTH stimulation testing; >15 μg/dL makes AI unlikely
• Serum and urine osmolality - To differentiate AI from SIADH
• Urine sodium concentration - Both AI and SIADH show elevated urine sodium (>40 mEq/L), but this helps exclude other causes
• Complete metabolic panel - Assess for hypoglycemia (common in AI) and renal function
• TSH - Required to exclude hypothyroidism per diagnostic criteria 1

Imaging Already Available

The CT scan showing a 4 cm solid adrenal mass in a post-nephrectomy RCC patient is highly concerning for metastatic disease. Per ESMO guidelines, abdominal and chest CT is mandatory for RCC staging 2. The presence of an adrenal mass with these electrolyte abnormalities creates a critical diagnostic scenario.

Distinguishing Adrenal Insufficiency from SIADH

Both conditions present with hyponatremia and can mimic each other, but key differences exist:

Adrenal Insufficiency Features (Present in This Case):

• Hyperkalemia (5.5 mmol/L) - This is the critical distinguishing feature
• Hypotension/orthostatic symptoms (dizziness)
• Weakness and fatigue
• Abdominal symptoms (distention)
• Structural adrenal pathology (4 cm mass)

SIADH Features (Less Likely Here):

• Normal or low potassium - SIADH does not cause hyperkalemia 1
• Euvolemic status
• Urine osmolality >500 mosm/kg
• Serum osmolality <275 mosm/kg
• Serum uric acid <4 mg/dL

The presence of hyperkalemia essentially excludes SIADH and points toward adrenal insufficiency. SIADH guidelines explicitly state diagnosis requires "absence of adrenal insufficiency" 1.

Immediate Management Algorithm

If Adrenal Insufficiency is Confirmed or Highly Suspected:

1. Initiate stress-dose glucocorticoid replacement immediately:

   • Hydrocortisone 100 mg IV bolus, then 50-100 mg IV every 6-8 hours
   • Do NOT wait for test results if patient is hemodynamically unstable

2. Fluid resuscitation:

   • 0.9% normal saline 1-2 liters IV rapidly
   • Monitor for fluid overload given abdominal distention

3. Correct hyperkalemia acutely 3:

   • Calcium gluconate 10% 10 mL IV over 2-3 minutes (cardiac membrane stabilization)
   • Regular insulin 10 units IV with 25g dextrose (shifts K+ intracellularly within 30 minutes)
   • Consider inhaled albuterol 10-20 mg nebulized
   • Monitor ECG for peaked T waves, prolonged QRS

4. Mineralocorticoid replacement (after initial stabilization):

   • Fludrocortisone 0.1 mg daily PO once patient can take oral medications
   • Only needed if primary AI confirmed (low cortisol + high ACTH)

If SIADH is Diagnosed (After Excluding AI):

Per guidelines, SIADH management depends on severity 1:

• Symptomatic or severe hyponatremia (Na <120 mEq/L):

  • 3% hypertonic saline IV
  • Target correction: 4-6 mEq/L in first 24 hours (avoid osmotic demyelination)

• Asymptomatic mild hyponatremia (Na 125-130 mEq/L):

  • Fluid restriction <1 L/day
  • Consider vasopressin receptor antagonists (tolvaptan) if refractory

Paraneoplastic Syndrome Considerations

RCC can cause multiple paraneoplastic syndromes 2:

• SIADH occurs in 1-5% of RCC cases 4, though more common with lung cancer
• Hypercalcemia (not present here - would need serum calcium checked)
• Erythrocytosis (check hemoglobin)
• Hyponatremia in metastatic RCC is associated with shortened survival and poor prognosis 5

However, the structural adrenal involvement makes metastatic AI far more likely than paraneoplastic SIADH in this case.

Critical Pitfalls to Avoid

1. Do not assume SIADH without excluding AI - The hyperkalemia is the red flag that demands AI evaluation
2. Do not delay glucocorticoid therapy if AI is suspected and patient is unstable - can be life-saving
3. Do not correct hyponatremia too rapidly - Risk of osmotic demyelination syndrome; target 4-6 mEq/L increase in first 24 hours
4. Do not attribute hyperkalemia solely to renal dysfunction (Cr 1.3 is only mildly elevated) - this degree of hyperkalemia with mild renal impairment suggests hormonal cause
5. Amlodipine (Norvasc) does not cause hyperkalemia 6, 7 - it's a calcium channel blocker, not affecting potassium homeostasis significantly

Oncologic Considerations

Given 7-month post-nephrectomy status with new adrenal mass:

• Biopsy of adrenal mass may be indicated before systemic therapy per ESMO guidelines 2, 8
• Restaging with chest CT to evaluate for other metastases 2, 8
• Consider brain imaging if neurologic symptoms develop
• Multidisciplinary oncology consultation for systemic therapy planning

Summary Recommendation

Obtain morning cortisol and ACTH immediately, initiate empiric stress-dose hydrocortisone if clinical suspicion is high, aggressively treat hyperkalemia, and provide IV fluid resuscitation. The constellation of hyponatremia, hyperkalemia, weakness, and adrenal mass in a post-RCC patient creates a medical emergency requiring immediate action. The hyperkalemia distinguishes this from SIADH and points directly toward adrenal insufficiency from metastatic disease.